Eli Lilly Targets Unapproved Weight-Loss Drugs with New Ad Campaign

The campaign warns consumers about the risks of compounded versions as FDA regulations tighten on GLP-1 drug alternatives.

• Eli Lilly launched its 'Healthy Skepticism' ad campaign to caution patients against unapproved versions of its weight-loss drug Zepbound and other GLP-1 medications.
• The FDA recently declared shortages of Zepbound, Wegovy, and Ozempic over, closing a loophole that allowed compounded versions to be sold during supply constraints.
• Compounded drugs, which are not FDA-approved, have raised safety concerns, prompting lawsuits from compounding pharmacies challenging the FDA's shortage status decision.
• Eli Lilly has joined one of the lawsuits to protect its interests and continues to lower Zepbound prices by offering higher doses in vials, expanding affordability.
• Telehealth company Hims & Hers, which profited from selling compounded versions of GLP-1 drugs, will soon cease those sales, impacting its business significantly.

3 Articles

Quartz Quartz